Triazole compounds and the use thereof as dopamine-D3 -ligands

A compound of formula I

• where
• Ar1 is phenyl which is unsubstituted or substituted by C1-C6-alkyl, OC1-C6-alkyl, CN, phenyl or halogen;
• A is a straight-chain or branched C4-C10-alkylene group or a straight-chain or branched group consisting of from 4 to 11 members selected from the group of from 3 to 10 methylene members and at least one member Z, wherein Z is selected from O, S, NR2, CONR2, COO, CO, a double bond and a triple bond, is
• 10 and
• Ar2 is pyrimidinyl which is unsubstituted or substituted by C1-C6-alkyl, halogen-C1-C6-alkyl, halogen-C1-C6-alkoxy, pyrrolyl or indolyl;
• R1 is C3-C6-cycloalkyl or C1-C6-alkyl which is unsubstituted or substituted by OH or OC1-C6-alkyl;
• the radicals R2, which can be identical or different, are H or C1-C6-alkyl which is unsubstituted or substituted by OH, OC1-C6-alkyl or phenyl;
• or a salt thereof with a physiologically tolerated acid.

A method for the treatment of a disease which responds to dopamine D3 receptor antagonists or dopamine D3 agonists and which is selected from the group of schizophrenia, depressions, neuroses, psychoses, Parkinson's disease and anxiety, which method comprises administering an effective amount of at least one compound of formula I

• where
• Ar1 is phenyl, naphthyl or a 5- or 6-membered heterocyclic aromatic ring having from 1 to 4 heteroatoms which are independently selected from O, S and N, where Ar1 is unsubstituted or substituted by 1, 2, 3 or 4 substituents selected from
• C1-C6-alkyl which is unsubstituted or substituted by OH, OC1-C6-alkyl, halogen or phenyl,
• C1-C6-alkoxy, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, halogen, CN, COOR2, NR2R2, NO2, SO2R2, SO2NR2R2, OH, and
• phenyl which is unsubstituted or substituted by C1-C6-alkyl, OC1-C6-alkyl, NR2R2, CN, CF3, CHF2, or halogen, and where the 5- or 6-membered heterocyclic ring may be fused to a phenyl ring;
• A is a straight-chain or branched C4-C10-alkylene group or a straight-chain or branched group consisting of from 4 to 11 members selected from the group of from 3 to 10 methylene members and at least one member Z, wherein Z is selected from O, S, NR2, CONR2, COO, CO, a double bond and a triple bond,
• B is a radical of the formula:
• Ar2 is phenyl, pyridyl, pyrimidinyl or triazinyl, where Ar2 is unsubstituted or substituted by from 1 to 4 substituents selected from
• OR2, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy-C1-C6-alkyl, halogen-C1-C6-alkyl, halogen-Cl-C6-alkoxy, halogen, CN, NO2, SO2R2, NR2R2, SO2NR2R2, a 5- or 6-membered carbocyclic, aromatic or non-aromatic ring and a 5- or 6-membered, heterocyclic aromatic or non-aromatic ring having from 1 or 2 heteroatoms which are selected from O, S and N, where the carbocyclic or heterocyclic ring is unsubstituted or substituted by C1-C6-alkyl, phenyl, phenoxy, halogen, OC1-C6-alkyl, OH, NO2 or CF3 and/or is optionally fused to a phenyl ring;
• and where Ar2 may be fused to a carbocyclic aromatic or non-aromatic ring or 5- or 6-membered heterocyclic aromatic or non-aromatic ring having 1 or 2 heteroatoms, selected from O, S and N,
• R1 is C3-C6-cycloalkyl or Cl-C6-alkyl which is unsubstituted or substituted by OH, OC1-C6-alkyl or phenyl;
• the radicals R2, which can be identical or different, are H or C1-C6-alkyl which is unsubstituted or substituted by OH, OC1-C6-alkyl or phenyl;
• or a salt thereof with a physiologically tolerated acid, to a subject in need of such treatment.

A compound of formula VIII

• where
• Ar1 is phenyl, naphthyl or a 5- or 6-membered heterocyclic aromatic ring having from 1 to 4 heteroatoms which are independently selected from O, S and N, where Ar1 is unsubstituted or substituted by 1, 2, 3 or 4 substituents selected from
• C1-C6-alkyl which is unsubstituted or substituted by OH, OC1-C6-alkyl, halogen or phenyl,
• C1-C6-alkoxy, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, halogen, CN, COOR2, NR2R2, NO2, SO2R2, SO2NR2R2, OH, and
• phenyl which is unsubstituted or substituted by C1-C6-alkyl, OC1-C6-alkyl, NR2R2, CN, CF3, CHF2, or halogen, and where the 5- or 6-membered heterocyclic ring may be fused to a phenyl ring;
• R1 is C3-C6-cycloalkyl or C1-C6-alkyl which is unsubstituted or substituted by OH or OC1-C6-alkyl;
• the radicals R2, which can be identical or different, are H or C1-C6-alkyl which is unsubstituted or substituted by OH, OC1-C6-alkyl or phenyl.